JP Morgan Chase
ALXN

JP Morgan Chase’s Alexion Pharmaceuticals ALXN Stock Holding History

JP Morgan Chase’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,600
Closed -$2.91M – 6522
2020
Q4 		$2.91M Hold
18,600
– – ﹤0.01% 3222
2020
Q3 		$2.09M Sell
18,600
-120,000
-87% -$12.9M ﹤0.01% 3194
2020
Q2 		$15.6M Buy
138,600
+65,400
+89% +$6.94M ﹤0.01% 1551
2020
Q1 		$6.57M Sell
73,200
-58,000
-44% -$5.69M ﹤0.01% 2054
2019
Q4 		$14.2M Buy
131,200
+600
+0.5% +$64.2K ﹤0.01% 1833
2019
Q3 		$12.8M Buy
130,600
+15,700
+14% +$1.77M ﹤0.01% 1939
2019
Q2 		$14.5M Buy
114,900
+39,800
+53% +$5.13M ﹤0.01% 1819
2019
Q1 		$10.2M Sell
75,100
-178,400
-70% -$22.2M ﹤0.01% 2033
2018
Q4 		$24.7M Buy
253,500
+163,600
+182% +$19.3M 0.01% 1324
2018
Q3 		$12.5M Buy
89,900
+1,900
+2% +$238K ﹤0.01% 2014
2018
Q2 		$10.9M Sell
88,000
-136,500
-61% -$16M ﹤0.01% 2072
2018
Q1 		$25M Buy
224,500
+166,500
+287% +$19.9M 0.01% 1361
2017
Q4 		$6.94M Buy
58,000
+10,000
+21% +$1.22M ﹤0.01% 2404
2017
Q3 		$6.64M Buy
48,000
+28,000
+140% +$3.8M ﹤0.01% 2334
2017
Q2 		$2.43M Sell
20,000
-74,200
-79% -$8.64M ﹤0.01% 2925
2017
Q1 		$11.4M Buy
+94,200
New +$12.1M ﹤0.01% 1842

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

JP Morgan Chase's ALXN Position: Q3 2021 in Review

JP Morgan Chase sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,748,795 shares — an estimated $321M sold.

JP Morgan Chase first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $1.21B in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • JP Morgan Chase reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • JP Morgan Chase sold 1,748,795 Alexion Pharmaceuticals shares in Q3 2021, an estimated $321M.
  • JP Morgan Chase first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • JP Morgan Chase's Alexion Pharmaceuticals position peaked at $1.21B in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on JP Morgan Chase's 13F filing for Q3 2021, filed 12 Nov 2021.